Scientific & Regulatory Communications
In biotech the science does not speak for itself. A communication failure looks like a scientific one: a muddy TPP, an investor story that contradicts the IB, a conference abstract that overclaims. Strategic scientific communication is a growth lever, not a late-stage polish.
BioVertex builds communication plans, supports regulatory writing and submission management, and shapes publication and conference strategy. Our extended team includes a senior medical writer (PhD, Johns Hopkins; IND through NDA/BLA) so the operational plan and the documents stay aligned.
Investor-ready scientific narratives are a core product: the same facts, different altitude, never a different truth.
What you get
- Scientific communication plan mapped to investors, regulators, KOLs, and partners
- Regulatory writing coordination and submission-management support (protocols, IBs, CSRs, briefing docs via extended team)
- Publication and conference strategy that does not leak claims you cannot defend
- Investor and BD scientific narratives consistent with the TPP and the data
- Message architecture so every deck, one-pager, and poster uses the same spine
Who this is for
Preclinical and clinical-stage companies preparing filings or raises, platforms that must explain a new modality, and CEOs who are tired of rewriting the story for every room.
Related reading: How Strategic Scientific Communication Sets Companies Apart. VC diligence and portfolio buildout live on For VC Firms.